Twice-daily radiation linked to better quality of life in lung cancer trial
A follow-up analysis of the NRG-LU005 lung cancer trial suggests that twice-daily radiation therapy is associated with better long-term quality of life compared to once-daily schedules. While the study did not improve overall survival rates, the findings offer new insights into patient-reported outcomes.
Why it matters
These findings help clinicians optimize treatment protocols to improve the daily living experience for patients undergoing aggressive cancer therapy.
edited by Gaby Clark , reviewed by Andrew Zinin
This article has been reviewed according to Science X's editorial process and policies . Editors have highlighted the following attributes while ensuring the content's credibility:
Add as preferred source Credit: Unsplash/CC0 Public Domain Previously, the primary endpoint results of the NRG-LU005 (NCT03811002) study assessing the addition of the immunotherapy drug atezolizumab (Tecentriq) to standard-of-care concurrent chemoradiation for limited-stage small-cell lung cancer were reported at the American Society for Radiation Oncology 2024 Annual Meeting. Those results showed that adding atezolizumab did not improve overall survival (OS) for this patient population.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in